Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Helena Earl

Professor Emeritus of Clinical Cancer Medicine

University of Cambridge

United Kingdom

Has grant

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

50%

Pharmacology

40%

Oncology

60%

Adjuvant Therapy

40%

Cancer Biology

30%

Neoadjuvant Therapy

30%

Gynecologic Oncology

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Recent Grants

Grant: Close

ARTemis - Translational

Open Date: 2016-04-01

Close Date: 2019-03-01

Grant: Close

PARTNER

Open Date: 2016-04-01

Close Date: 2020-03-01

Grant: Close

International Rare Cancers Initiative – HGUS Study

Open Date: 2013-11-01

Close Date: 2017-11-01

Grant: Close

ARTemis

Open Date: 2009-04-01

Close Date: 2014-03-01

Grant: Close

ARTemis

Open Date: 2009-04-01

Close Date: 2014-03-01

Articles13

The PARTNER trial of neoadjuvant olaparib in triple-negative breast cancer.

Article Link

Year:

2024

Safe de-escalation of chemotherapy in HER2-positive early breast cancer.

Article Link

Year:

2024

The Lancet Breast Cancer Commission

Article Link

Year:

2024

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Article Link

Year:

2023

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.

Article Link

Year:

2023

The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge

Article Link

Year:

2022

Magnetization transfer imaging of ovarian cancer: initial experiences of correlation with tissue cellularity and changes following neoadjuvant chemotherapy.

Article Link

Year:

2022

Multi-omic machine learning predictor of breast cancer therapy response.

Article Link

Year:

2021

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.

Article Link

Year:

2021

Profiteering from vaccine inequity: nudge pharma towards "doing well by doing good".

Article Link

Year:

2021

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis

Article Link

Year:

2020

Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

Article Link

Year:

2020

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK.

Article Link

Year:

2020

Collaborators9

Daniel Rea

Professor of Medical Oncology

University of Birmingham

UNITED KINGDOM

Janet Dunn

Professor of Clinical Trials and Head of Cancer trials

University of Warwick

UNITED KINGDOM

Jeremy Braybrooke

Honorary Associate Professor

University of Bristol

UNITED KINGDOM

Robert Stein

Professor of Breast Oncology

University College London

UNITED KINGDOM

Pericles Foroglou

Associate Professor

Aristotle University of Thessaloniki

GREECE

Diana M Eccles

University of Southampton

UNITED KINGDOM

Jean Abraham

Professor of Precision Breast Cancer Medicine

University of Cambridge

UNITED KINGDOM

Stuart McIntosh

Clinical Senior Lecturer in Surgical Oncology

The Queen's University Belfast

UNITED KINGDOM

Robert Winqvist

Professor

University of Oulu

FINLAND

How do I reach out?

Meet Kite AI